Scholarlink

<p>With the aim of developing a new vaccine candidate using a recombinant baculovirus (rBV) expressing the Junín virus (JUNV) GP1 and GP2 proteins on its surface, a pBacPAK9 vector containing the BV-GP64 signal peptide, the JUNV GP1–GP2 and the transmembrane domain of the vesicular stomatitis virus G (VSV-G) protein were synthesized. This plasmid was co-transfected with the bApGOZA bacmid into Sf9 cells. The rBV was recovered from the supernatant. Protein expression was confirmed with a human serum by Western blot and with an anti-GPC monoclonal antibody by IFI staining and virometry. In an ELISA test, mice immunized with rBV exhibited specific antibody levels that also showed neutralizing properties in a plaque reduction test compared to controls. Guinea pigs immunized with rBV and challenged with JUNV showed partial protection compared to the Candid#1 vaccine. We have developed an rBV surface display platform to validate a potential JUNV vaccine candidate.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

A New Vaccine Candidate Expressing JUNV GP1–GP2 Against Argentine Hemorrhagic Fever Based on Baculovirus Surface Display

  • 期刊论文

  • 发表日期：

    2025年6月13日

查看全文
  • Carla Tomatis,
  • Mara C. A. M. Aguiar,
  • Nancy Charo,
  • Silvia Aquila,
  • Pablo D. Thomas,
  • Paula N. Arrías,
  • Matías L. Pidre,
  • Víctor Romanowski,
  • Laura Riera,
  • Julia Brignone,
  • Andrea Maiza,
  • Eugenio Antonio Carrera Silva,
  • María Florencia Ferrer,
  • Ricardo Martín Gómez

摘要

With the aim of developing a new vaccine candidate using a recombinant baculovirus (rBV) expressing the Junín virus (JUNV) GP1 and GP2 proteins on its surface, a pBacPAK9 vector containing the BV-GP64 signal peptide, the JUNV GP1–GP2 and the transmembrane domain of the vesicular stomatitis virus G (VSV-G) protein were synthesized. This plasmid was co-transfected with the bApGOZA bacmid into Sf9 cells. The rBV was recovered from the supernatant. Protein expression was confirmed with a human serum by Western blot and with an anti-GPC monoclonal antibody by IFI staining and virometry. In an ELISA test, mice immunized with rBV exhibited specific antibody levels that also showed neutralizing properties in a plaque reduction test compared to controls. Guinea pigs immunized with rBV and challenged with JUNV showed partial protection compared to the Candid#1 vaccine. We have developed an rBV surface display platform to validate a potential JUNV vaccine candidate.